Larimar Therapeutics, Inc.
LRMR
Rank in Stocks
#15440
Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates... Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.
Share Price
$2.53
Last synced: 2026-11-09
Market Cap
$262.82M
Change (1 day)
5.86%
Change (1 year)
-30.30%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade Larimar Therapeutics, Inc. (LRMR)
Category
Healthcare
EPS for Larimar Therapeutics, Inc. (LRMR)
EPS as of June 2026 TTM: $-1.99
According to Larimar Therapeutics, Inc.'s latest financial reports, its current EPS (TTM) is $-1.99. At the end of 2025 the company had an EPS of $-2.27, a decrease compared to its 2024 EPS of $-1.32.
EPS history for Larimar Therapeutics, Inc. from 2011 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-1.99 | -12.33% |
| 2025 | $-2.27 | 71.97% |
| 2024 | $-1.32 | 57.14% |
| 2023 | $-0.84 | -36.84% |
| 2022 | $-1.33 | -54.61% |
| 2021 | $-2.93 | -17.70% |
| 2020 | $-3.56 | 41.83% |
| 2019 | $-2.51 | -89.02% |
| 2018 | $-22.85 | 0.40% |
| 2017 | $-22.76 | -10.53% |
| 2016 | $-25.44 | -23.65% |
| 2015 | $-33.32 | 120.08% |
| 2014 | $-15.14 | 131.50% |
| 2013 | $-6.54 | 2.19% |
| 2012 | $-6.40 | 5.44% |
| 2011 | $-6.07 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -886.93% |
US
|
|
| $-7.07 | 255.28% |
US
|
|
| $-5.29 | 165.83% |
AU
|
|
| $12.88 | -747.24% |
BE
|
|
| $21.56 | -1,183.42% |
NL
|
Questions about Larimar Therapeutics, Inc.'s earnings per share (EPS)
What is Larimar Therapeutics, Inc.'s earnings per share (EPS)?
Larimar Therapeutics, Inc.'s earnings per share (EPS) over the last twelve months is $-1.99, as of Jun 2026.
What was Larimar Therapeutics, Inc.'s earnings per share (EPS) in 2025?
In 2025, Larimar Therapeutics, Inc.'s earnings per share (EPS) was $-2.27, compared with $-1.32 in 2024.
How has Larimar Therapeutics, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Larimar Therapeutics, Inc.'s earnings per share (EPS) was highest in 2023 ($-0.84) and lowest in 2020 ($-3.56).
How does Larimar Therapeutics, Inc.'s earnings per share (EPS) compare with similar companies?
Larimar Therapeutics, Inc.'s earnings per share (EPS) ($-1.99) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.